Recent Vioxx News
 |
Read all news about Vioxx.
Get information about class-action lawsuits, settlement attourneys and how they achieved the Merck class action lawsuit settlement in september 2008. Furthermore read about the health risks taking Vioxx, the side effects of this defective prescription drug.
- Efficacy of a vitamin/nutriceutical formulation for early-stage alzheimer's disease: a 1-year, open-label pilot study with an 16-month caregiver extension
- Plaintiff attorneys say mdl judge has no jurisdiction on fees
- Vioxx mdl judge denies motion to recuse and to vacate discovery order
- Vioxx plaintiff seeks more time to file expert report
- A study on improvement of solubility of rofecoxib and its effect on permeation of drug from topical formulations
- Immune globulin/rofecoxib: thrombocytopenia and myocardial infarction: case report
- Texas appeals court reinstates vioxx suit it previously dismissed
- The risk of acute myocardial infarction with etodolac is not increased compared to naproxen: a historical cohort analysis of a generic cox-2 selective inhibitor
- Cyclooxygenase type 1 (cox-1) vs. cyclooxygenase type 2 (cox-2) as a determinant of the basal tone in the internal anal sphincter.
- Drugs trial payout victory
- 5th circuit affirms denial of hmos' reimbursement suit stemming from vioxx settlement
- Vioxx lawyer says merck seeks to increase his clients' trial expenses
- Litigant warned against 'contumacious conduct' petitions supreme court
- Judge grants transfer of remand question to vioxx mdl court
- Vioxx fraud plaintiffs say no obstacles exist to class treatment of claims
- New jersey judge stays shareholders suit
- Litigator settles suit over tardy fda production
- Patients safety concerns as drug regulators pressured to approve new treatments quicker
- Protective effect of latex of calotropis procera in freund's complete adjuvant induced monoarthritis
- Nonselective and cyclooxygenase-2-selective nsaids and acute kidney injury.
- Media reports on pharmaceuticals may be skewed towards commercial interests
- Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (nsaids) among healthy individuals: a nationwide cohort study.
- Cv events persist for one year after stopping vioxx.
- Unapproved delay in vioxx 3rd-party suit judged 'a waste of time'
- Merck removes new york lawsuit for medicaid recovery
- New jersey high court agrees to consider federal preemption
- Union's suit claims it spent money on 'overpriced' vioxx
- Merck says courts have already ruled against a consumer vioxx class
- Florida sues merck, calls vioxx marketing a deceptive trade practice
- Vioxx mdl judge orders prescription provider to produce or face fines
 (No Ratings Yet) Loading ... |
